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ABSTRACT 
Aims: Our aim was to identify circulating microRNAs (miRNAs) associated with acute heart failure (AHF).   
Methods and Results: Plasma miRNA profiling included 137 patients with AHF from 3 different cohorts, 20 
with chronic heart failure (CHF), 8 with acute exacerbation of chronic obstructive pulmonary disease 
(COPD) and 41 healthy controls. Levels of circulating miRNAs were measured using quantitative reverse 
transcription–polymerase chain reaction (qRT-PCR). Plasma levels of miRNAs in patients with AHF were 
decreased compared to CHF patients or healthy subjects, whereas no significant changes were observed 
between acute COPD patients and controls. Fifteen miRNAs found in the discovery phase to differ most 
significantly between healthy controls and patients with AHF were further investigated in an extended 
cohort of 100 AHF patients at admission and separate cohort of 18 AHF patients at different time points. 
Out of these 15 miRNAs, 12 could be confirmed in an additional AHF validation cohort and 7 passed the 
Bonferroni correction threshold (miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-106a-5p, miR-
199a-3p, and miR-652-3p, all p<0.00005). A further drop in miRNA levels within 48 hours after AHF 
admission was associated with an increased risk of 180 day mortality in a subset of the identified miRNAs. 
Conclusions: Declining levels of circulating miRNAs were associated with increasing acuity of heart failure.  
Early in-hospital decreasing miRNA levels were predictive for mortality in a subset of miRNAs in patients 
with AHF. The discovered miRNA panel may serve as a launch-pad for molecular pathway studies to 
identify new pharmacological targets and miRNA-based therapies. 
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INTRODUCTION 
 
MicroRNAs (miRNAs) are a class of small (approximately 22 nucleotides in length) non-coding RNAs that 
are potent regulators of gene expression at the post-transcriptional level (1,2). MiRNAs are released into 
the systemic circulation, are remarkably stable and are thought to some extent reflect miRNA expression in 
tissue (3). Thus, circulating miRNAs are potential biomarkers for a variety of pathological conditions, 
including heart failure (HF) (3,4). Moreover, miRNAs may improve our understanding of the 
pathophysiology underlying HF which may aid the development of novel, targeted therapies. 
Specific circulating miRNA profiles have previously been described in patients with chronic heart failure 
(CHF) (5,6-9). A few studies have examined miRNAs in acute heart failure (AHF). Two studies measured 
miRNA levels in patients presenting at the emergency department with acute dyspnea and both revealed 
one or more miRNAs as distinctive markers of AHF (10,11). In addition, Corsten et. al. described specific 
miRNAs involved in myocardial damage, and found miR-499 to be substantially increased in patients with 
AHF compared to healthy controls  (12).  
However, most studies were limited by a small sample size and lack of validation. We now report a miRNA 
signature in a variety of independent cohorts with a larger number of AHF patients in which we additionally 
investigate the association between circulating miRNA levels and clinical outcome. 
 
MATERIALS AND METHODS 
Study design and procedures 
Study subjects originated from 5 separate cohorts in various states of HF, ranging from AHF to stable CHF, 
and healthy controls.  
Discovery phase: 
In the discovery phase, 30 plasma samples from 10 patients hospitalized for AHF (AHF-admission, 
PROTECT cohort), 10 patients with CHF and 10 healthy controls (Telosophy cohorts) were analyzed.  
The AHF cohort was selected from the Placebo-controlled Randomized Study of the Selective A1 
Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart 
Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) 
trial (13). Stable CHF patients and healthy control subjects originated from the Telosophy study (14). Key 
exclusion criteria for healthy controls were known atherosclerotic disease, HF or a family history of 
premature cardiovascular disease. 
Extended cohorts: 
For the extended cohort, additionally to the 10 AHF PROTECT blood samples from the discovery phase, 
100 PROTECT blood samples were analyzed at four different time points: admission for AHF (AHF- 
admission), after 24 hours (AHF-24h admission), 48 hours (AHF-48h admission) and day 7 after admission 
(AHF-7d admission). MiRNA patterns at discharge (AHF-discharge) and 6 months after hospitalization 
(AHF-6m follow-up) for AHF were measured in plasma samples from 18 patients from the Coordinating 
Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) study (15). In addition to 
the discovery cohort 10 plasma samples of healthy controls and 10 samples of CHF patients, plasma 
samples from 14 age and sex matched healthy controls were analyzed (Telosophy). 
Validation cohorts: 
Following the analysis of the discovery and extended cohorts, obtained findings were validated in 3 
independent cohorts:  AHF patients (9 samples, Wroclaw cohort), CHF patients (10 samples, Beneficial 
cohort) and patients with an acute exacerbation of COPD (8 samples, Paris cohort) (16). Matching controls 
from the same center (8 originating from Paris, 9 from Wroclaw) were included into the validation study. 
Briefly, the Wroclaw cohort comprised patients admitted to the hospital with a diagnosis of AHF in all cases 
based on the presence of signs and symptoms of AHF requiring intravenous treatment (loop diuretics, 
nitroglycerin and/or inotropes). Patients with acute coronary syndrome as underlying cause of AHF were 
excluded (Figure 1).  
MiRNA profiling: isolation, cDNA synthesis and qRT-PCR. 
Plasma sample processing for all cohorts and miRNA profiling were conducted in the same laboratory, 
under the same conditions. In the discovery and validation phases circulating miRNA expression profiling 
was performed by using commercially available Serum/Plasma Focus microRNA PCR panel (V2.M) 
(Exiqon, Vedbaek, Denmark). The panel consists of the 375 most well described and abundant human 
circulating miRNAs that were detected in human serum/plasma. The 15 miRNAs selected based on the 
results from the discovery cohort were analyzed in the extended cohorts using customized Serum/Plasma 
microRNA PCR panel (Exiqon, Vedbaek, Denmark). 
RNA was isolated from 200 μl of plasma using the miRCURY RNA isolation kit – Biofluids (Exiqon, 
Vedbaek, Denmark). Reverse transcription reactions were performed using the Universal cDNA Synthesis 
Kit (Exiqon, Vedbaek, Denmark). For each reaction, 4 μl of RNA was used. A total of 226 out of 375 
miRNAs were detected in qRT-PCR analysis of the plasma samples. The remaining miRNAs were below 
detection level. All the procedures were performed according to the manufacturer’s instructions. See 
Supplementary Information for further details. 
Statistical methods 
Differences in miRNA expression between different groups were determined by a two-tailed unpaired t-test. 
Bonferroni correction was applied to P-values to adjust for multiple testing. The Bonferroni correction for P-
value sets the significance cut-off at p/n, where P is 0.05 and n number of tests.  The significance threshold 
was set to a ≥2-fold change with a corrected P-value ≤0.00022 (discovery and validation cohorts, dataset 
with 226 detected miRNAs) or ≤0.0033 (extended cohorts, dataset with 15 detected miRNAs) for the 
comparison of plasma miRNA expression between studied conditions and time points. 
Cox proportional hazards regression was performed to examine associations with outcome. Survival 
analysis included Harrell’s C-index calculation. The exact binomial test was used to estimate the likelihood 
of the occurrence of multiple miRNAs being significant predictors of outcome, by calculating if the amount of 
significant observations is more than expected by chance.  P-values ≤0.05 were considered significant. All 
statistical analyses where performed using GenEx Professional version and R: A language and 
Environment for Statistical Computing, version 3.0.3 (R Foundation for Statistical Computing, Vienna, 
Austria). 
 
RESULTS 
Patient characteristics  
Table 1 shows the demographic and clinical characteristics of all cohorts used in this study. Plasma NT-
proBNP concentrations differed markedly between the cohorts in the discovery and extended study being 
lowest in healthy controls and highest in patients with AHF at the time of admission (Table 1).  
Circulating miRNA profiling in acute heart failure patients 
Of the 226 miRNAs detected during the discovery phase, 40 remained significantly different in AHF patients 
compared to healthy controls after the Bonferroni correction (Table S1). Figure 2A provides an overview of 
the initial screening data depicted in a volcano plot. A panel of 15 miRNAs with a >4 fold change was 
selected for further analysis, and included miR-423-5p as one of the miRNAs reported most consistently 
with different levels in HF patients (6,8,10). 
Differential miRNA levels in various stages of heart failure 
The association of the selected 15 miRNAs with AHF was further supported by a highly consistent pattern 
of decreased miRNA levels with increased acuity of HF (Figure 2A). The lowest levels of miRNAs were 
observed in patients from admission for AHF to day 7 (PROTECT-extended cohort). The miRNAs of the 
panel gradually increased in COACH AHF patients at discharge (AHF-discharge) and converged at 6 
months (AHF-6m follow-up) towards the CHF (Telosophy) levels. A significant trend over the different time 
points was observed for all miRNAs (all p<0.001), as shown in Figure 2B. The results were confirmed using 
unsupervised hierarchical cluster analysis, which showed a clear separation of patients with AHF from the 
healthy controls and CHF patients (Supplementary Figure S1).  
 
Circulating miRNAs profiles in the validation cohorts 
Plasma levels of 12 miRNAs out of 15 that were identified during the discovery phase were also shown to 
be significantly decreased in AHF (Wroclaw) compared to CHF (Beneficial) patients and healthy controls 
(Table S2, Table S3), of which 7 crossed the false discovery rate settled to correct for multiple testing; miR-
18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-106a-5p, miR-199a-3p, and miR-652-3p, respectively. 
The validation results are summarized in Figure 3. In the AHF validation cohort, the levels of these 7 
miRNAs were significantly lower in AHF patients compared to healthy controls (Figure 3A, B). There were 
no differences in miRNA levels between patients admitted with an acute exacerbation of COPD (Paris) and 
healthy controls (Figure 3C, D). The differentiation between AHF patients from both discovery and 
validation cohorts and healthy controls is clearly shown by the result of the principal component analysis 
(PCA) depicted in Figure 3E.  
Circulating miRNAs related to clinical outcome 
With univariable Cox proportional hazards analysis, the prognostic value of the miRNA panel in the 100 
AHF (PROTECT-extended cohort) patients was assessed. After admission, a further decrease in miRNA 
levels after 48 hours in a subset of 7 out of 15 miRNAs (let-7i-5p, miR-18a-5p, miR-18b-5p, miR-223-3p, 
miR-301a-5p, miR-423-5p miR-652-3p) was found to be predictive for 180 day mortality (Table 2). Two out 
of the seven miRNAs (miR-18a-5p and miR-652-3p) passed Bonferroni correction in the AHF validation 
cohort. The result of the exact binomial test was highly significant (p<3.518*10-6), thus the likelihood of the 
occurrence of multiple miRNAs predicting outcome by chance is highly improbable. Harrell’s C-indexes 
were calculated to obtain the discriminative value of our models to predict outcome, which ranged in the 
significant miRNAs from 0.63 to 0.70. Furthermore, the directionality of the Hazard Ratios of all 15 miRNAs 
(HR>1) supports the consistency of these findings.   
 
DISCUSSION 
In the present study we identified a panel of 15 circulating miRNAs associated with AHF that were 
consistently decreased in patients with AHF compared to both patients with CHF and healthy controls. 
Moreover, decreasing levels of circulating miRNAs were associated with increasing acuity of HF.  A further 
drop in 7 out of 15 miRNAs early during hospitalization was associated with an increased risk of mortality 
within 180 days. Validation in an independent cohort of patients with AHF confirmed this panel of miRNAs 
and led to 7 AHF specific miRNAs of which miR-18a-5p and miR-652-3p were predictive for 180 day 
mortality. Another cause of acute breathlessness (acute exacerbation of COPD) was not related to a 
change in circulating miRNA profiles compared to controls, implying that our results were not a 
consequence of general respiratory distress.   
Involvement of miRNAs in heart failure 
Recent evidence suggests that miRNAs play an important role in cardiac development and are involved in 
the pathogenesis of cardiovascular diseases, including HF (17-19).  A relationship between miRNAs and 
cardiac tissue development was shown by deleting the miRNA-processing enzyme DICER in 
cardiomyocytes and epicardium tissue in mice. These mutations cause profound cardiac defects and lead 
either to embryonic or neonatal death (17-19). Other studies reported that the hearts of these knock-out 
mice developed hypertrophy, fibrosis and ventricular dilatation, resulting in HF (17). The discovery that 
miRNAs are secreted and extracellularly measurable in blood and other body fluids has stimulated research 
on circulating miRNAs. The ongoing results suggested a differential diagnostic utility of circulating miRNAs 
in HF and several studies investigated the diagnostic potential of circulating miRNAs in HF (8,20). 
Furthermore, a more accurate discrimination between HF with preserved ejection fraction (HFpEF) and HF 
with reduced ejection fraction (HFrEF) have been proposed by using circulating miRNAs ((21-23). However, 
most of the studies on circulating miRNAs in HF have been conducted either in small numbers of patients 
or only include patients with CHF (5-8). Circulating miRNA patterns related to AHF are not well described. 
The HF specific panel of 7 circulating miRNAs identified in our study overlaps with published results of other 
related investigations. Although several investigators report about an upregulation of miRNAs, more recent 
publications describe lower levels of miRNAs to be associated with cardiac disease, in concordance with 
our study (6,24-26). For example, a study of patients with symptomatic HF showed that 24 circulating 
miRNAs were decreased compared to control subjects, including miR-26b-5p, miR-223-3p, miR-16-5p, 
miR-30e-5p, miR-423-5p, miR-27a-3p and miR-18a-5p (6) and also Watson et al. found that all of the 5 
identified miRNAs were reduced in HF patients (21). 
The identified miRNAs have been shown to play a role in important pathophysiological mechanisms 
implicated in HF development such as cardiomyocyte proliferation, myocardial matrix remodeling and 
cardiac hypertrophy (Table S4).  
MiR-199a-3p is able to promote cardiomyocyte proliferation in the heart of mice and stimulates cardiac 
regeneration after induced myocardial infarction (27). A relationship between hypoxic conditions and 
miRNA expression has been described for miR-199a with possible cardiac involvement of the miR-199a-
214 cluster, inducing the shift from fatty acid utilization to glucose metabolism in HF (28). Dysregulation of 
miR-18a-5p, another member of our panel, is involved in vascular smooth muscle cell differentiation by 
targeting Syndecan4 in a carotid artery injury model (29). Human and canine cardiomyocytes expression 
levels of miR-26a and miR-26b were reduced in subjects with atrial fibrillation (30). Several miRNAs in our 
panel were associated with cardiac hypertrophy. MiR-18b, miR-26b, miR-27a and miR-199a might play an 
important role in the development of cardiac hypertrophy (31-34), while overexpression of miR-26b and 
miR-27a in vitro resulted in less hypertrophic cardiomyocytes (35,36). Bernardo et al. reported about the 
effect of silencing miR-652 in a hypertrophic mouse model, which improved cardiac function and attenuated 
hypertrophy and adverse remodeling (37).  
Circulating miRNAs have the potential to serve as novel prognostic markers. Pilbrow et al. reported that 
plasma concentrations of miR-652 in the lowest tertile were associated with readmission for HF in patients 
with an acute coronary syndrome (38).   Cakmak et al found that miR-182 could serve as a significant 
independent predictor for cardiovascular mortality in systolic heart failure (39) . Earlier, Fukushima et al. 
found that level of miR-126 in plasma of patients with congestive heart failure correlated negatively with 
disease severity, assessed with the New York Heart Association Functional Classification (NYHA) (40). 
Furthermore, the dynamic change in plasma-derived miR-133b can reflect early myocardial injury after 
heart transplantation (41). In our study the subset of miRNAs were found in lower levels in patients with 
AHF compared to healthy individuals. Moreover, for the first time, early in-hospital changes of miR-18a-5p 
and miR-652-3p were described as significant independent predictors of 180-day mortality in AHF patients. 
The analysis had some limitations however, such as a lack of validation of prognostic value in other 
independent cohorts and a relatively small sample size. 
The origin and role of circulating miRNAs is currently under investigation. Some studies have suggested 
that plasma concentrations of miRNAs might reflect concentrations of these miRNAs in organs and tissue, 
for example in the heart (12,42,43). Notably, all 7 miRNAs validated in our plasma screen (miR-18a-5p, 
miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-106a-5p, miR-199a-3p, and miR-652-3p) are expressed in 
cardiac tissue. 
 It has been postulated that tissue cells try to compensate for miRNA deficiency by extracting them from the 
circulation (44). However, the role of miRNA in cell-to-cell communication is poorly understood, and 
whether circulating miRNAs are sufficient to exert physiological effect in cells remains to be proven. We 
hypothesize that under pathophysiologic conditions (e.g. prolonged hypoxia or stretch), cells do not function 
properly, which could lead to reduced miRNA production and excretion. Once the pathophysiologic 
conditions improve, miRNA production and excretion may recover and lead to restored plasma 
concentrations.  
Strengths and limitations 
We performed a relatively large and robust study in order to identify a novel miRNA signature of AHF. This 
is the first study to show gradual changes in circulating miRNA levels depending on the acuity of HF. 
However, our study has several limitations. Although this is the largest AHF cohort reported to date, its size 
remains modest. Furthermore, we did not perform any functional investigation of the identified miRNAs. The 
miRNA panel used for the initial screening consisted of only 375 well characterized miRNAs and might not 
include miRNAs with low circulating levels in healthy patients. Further, due to variability in expression levels 
and strict statistical correction we may have missed other miRNAs related to AHF.  
Conclusion 
We identified a distinct panel of circulating miRNAs decreased in AHF. The association of these miRNAs 
with AHF was further supported by a highly consistent pattern of increased miRNA levels with decreasing 
acuity of HF. A further drop in a subset of miRNAs early after hospital admission for AHF was associated 
with increased mortality through 180 days. A better understanding of the role of these miRNAs in AHF may 
provide insights into underlying disease mechanisms, potentially leading to better and more targeted 
management and therapies. 
Translational perspectives: 
Circulating miRNAs might become new biomarkers in HF. Expression levels of our selected panel of 
miRNAs was distinctly and consistently lower in patients with AHF than in patients with CHF, acute 
exacerbation of COPD and control subjects, suggesting diagnostic value of these miRNAs. We also 
demonstrated a possible association between mortality and a number of miRNAs. This suggests that these 
miRNAs might predict those AHF patients at risk for a poorer outcome. Moreover, it remains to be 
established whether the identified miRNA set is able to predict not only outcome but also response to 
treatment and further prospective studies should explore its performance in guiding therapy in AHF. Finally, 
these miRNAs may become targets for therapy once we learn more about their role in the pathology and 
progression of AHF.  
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FIGURE LEGENDS  
 
Figure 1. Study design 
 
 
Figure 2. MiRNA levels in plasma samples of AHF patients at various time points 
 
(A) Circulating levels of miRNAs of interest in plasma samples were quantified by qRT-PCR assay. 
Values are plotted as geometrical mean ±SD, **P<0.001. 
Intercept shows Volcano plot illustrating a cluster of the 15 circulating miRNAs that changed most 
significantly between AHF patients and healthy controls. Log2 ratio of fold change (x-axis) is plotted 
against statistical significance based on –log10 (y-axis) for each miRNA. miRNAs plotted in green 
passed the Bonferonni correction (based on p ≤ 0.00022; represented by green dash line) and changed 
more than 2-fold (represented by two black vertical lines). MiRNAs plotted in yellow did not pass 
Bonferroni correction but changed more than 2-fold compared to controls. Statistically insignificant 
miRNAs but with a change of more than 2-fold are plotted in red. Biologically and statistically 
insignificant miRNAs are plotted in grey. (B) MiRNA levels per cohort (median [IQR]) including p-for-
trend. MiRNAs shown to be significantly changed for both discovery and validation cohorts are 
highlighted in bold. 
Figure 3. Profiling of circulating miRNAs in validation cohorts  
(A) Volcano plots showing miRNAs levels in plasma samples of AHF patients compared to healthy 
controls. Forty-four percent of the significantly lowered miRNAs detected in the validation cohort 
overlapped with the decreased miRNAs found in the discovery phase. Log2 fold change in miRNAs 
level is plotted on the x-axis and false discovery rate-adjusted significance (Bonferroni-correction, p ≤ 
0.00022; represented by green dash line) is plotted on the y-axis (–log10 scale). MiRNAs plotted in 
green passed the Bonferonni correction and changed more than 2-fold. MiRNAs plotted in yellow did not 
pass Bonferroni correction but changed more than 2-fold compared to controls. Statistically insignificant 
miRNAs but with a change of more than 2-fold are plotted in red. Biologically and statistically 
insignificant miRNAs are plotted in grey (B) 7 miRNAs out of 15 were consistently and significantly 
changed in the discovery and validation cohorts. (C) Volcano plots showing miRNA levels in plasma 
samples of COPD patients compared to healthy controls. Log2 fold change in miRNAs level is plotted 
on the x-axis and false discovery rate-adjusted significance (Bonferroni-correction, p ≤ 0.00022; 
represented by green dash line) is plotted on the y-axis (–log10 scale). MiRNAs plotted in yellow did not 
pass Bonferroni correction but changed more than 2-fold compared to controls. Statistically insignificant 
miRNAs but with a change of more than 2-fold are plotted in red. Biologically and statistically 
insignificant miRNAs are plotted in grey. (D) There were no differences in miRNAs level between COPD 
patients and healthy subjects. (E) Graph of principal components analysis (PCA), showing partial 
differentiation between patients with AHF from both discovery and validation cohorts (depicted in red), 
COPD patients (depicted in green) and healthy subjects (depicted in blue). Each square represents one 
patient. (F) MiRNA levels in plasma samples of CHF patients of the discovery phase (CHF T, 
Telosophy, discovery cohort) compared to CHF patients of the validation phase (CHF B, Beneficial, 
validation cohort). 
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